Simultaneous Pancreas and Kidney Transplant DRG Reimbursement

DRG 019 represents simultaneous pancreas and kidney transplant performed in patients receiving hemodialysis and captures a complex, high-resource inpatient clinical episode. Accurate assignment matters for inpatient reimbursement because it aligns payment with the substantial surgical, transplant care, and dialysis services required.

DRG 019 Overview

DRG 019 covers simultaneous pancreas and kidney transplant procedures performed with maintenance hemodialysis in patients who require renal replacement therapy perioperatively. This Diagnosis-Related Group reflects a high-resource, complex surgical and medical course involving multi-organ transplantation and perioperative dialysis management. It matters for Medicare payment because reimbursement is intended to account for the intensive operative, transplant immunology, and dialysis-related costs associated with these cases. Accurate classification affects hospital revenue and compliance with Centers for Medicare & Medicaid Services inpatient payment rules.

Perioperative immunosuppression optimization trials: randomized or prospective cohort studies comparing different immunosuppressive regimens, dosing strategies, or induction agents in simultaneous pancreas-kidney transplant recipients who require perioperative hemodialysis. These studies enroll patients with end-stage renal disease and insulin-dependent diabetes undergoing combined transplant to determine early graft function, rates of acute rejection, and complications related to dialysis timing. Results are directly relevant to transplant centers and payers because they can influence length of stay, readmission rates, and short-term graft survival, which drive inpatient resource use and reimbursement under this DRG.
Comparative effectiveness studies of dialysis management strategies around transplant: pragmatic observational studies or controlled trials comparing immediate perioperative hemodialysis versus delayed or alternative renal replacement approaches (e.g., continuous therapies) in patients undergoing simultaneous pancreas-kidney transplant. The patient population includes individuals with varying degrees of residual renal function and comorbid cardiovascular instability, and the research question focuses on cardiovascular events, fluid balance, metabolic control, and early graft perfusion. Findings inform clinical pathways that affect ICU utilization, complication rates, and downstream costs, helping providers and payers optimize care coordination and resource allocation for this complex DRG.
Longitudinal outcomes and health services research on post-discharge graft survival, quality of life, and cost-effectiveness: prospective cohort studies or registry-based analyses following recipients of simultaneous pancreas-kidney transplants who required perioperative hemodialysis to assess one- to five-year graft function, diabetes independence, infection rates, and health-related quality of life. These studies target the full spectrum of patients discharged after the index hospitalization and examine factors such as readmissions, outpatient dialysis needs, and immunosuppression-related complications. This research is critical for payers and hospitals because it links inpatient care decisions to long-term outcomes and total cost of care, informing reimbursement strategies, care pathways, and value-based contracting for the DRG.

Perioperative immunosuppression optimization trials: randomized or prospective cohort studies comparing different immunosuppressive regimens, dosing strategies, or induction agents in simultaneous pancreas-kidney transplant recipients who require perioperative hemodialysis. These studies enroll patients with end-stage renal disease and insulin-dependent diabetes undergoing combined transplant to determine early graft function, rates of acute rejection, and complications related to dialysis timing. Results are directly relevant to transplant centers and payers because they can influence length of stay, readmission rates, and short-term graft survival, which drive inpatient resource use and reimbursement under this DRG.
Comparative effectiveness studies of dialysis management strategies around transplant: pragmatic observational studies or controlled trials comparing immediate perioperative hemodialysis versus delayed or alternative renal replacement approaches (e.g., continuous therapies) in patients undergoing simultaneous pancreas-kidney transplant. The patient population includes individuals with varying degrees of residual renal function and comorbid cardiovascular instability, and the research question focuses on cardiovascular events, fluid balance, metabolic control, and early graft perfusion. Findings inform clinical pathways that affect ICU utilization, complication rates, and downstream costs, helping providers and payers optimize care coordination and resource allocation for this complex DRG.
Longitudinal outcomes and health services research on post-discharge graft survival, quality of life, and cost-effectiveness: prospective cohort studies or registry-based analyses following recipients of simultaneous pancreas-kidney transplants who required perioperative hemodialysis to assess one- to five-year graft function, diabetes independence, infection rates, and health-related quality of life. These studies target the full spectrum of patients discharged after the index hospitalization and examine factors such as readmissions, outpatient dialysis needs, and immunosuppression-related complications. This research is critical for payers and hospitals because it links inpatient care decisions to long-term outcomes and total cost of care, informing reimbursement strategies, care pathways, and value-based contracting for the DRG.

OpenPayer

Summary & Overview

Simultaneous Pancreas and Kidney Transplant with Hemodialysis: Inpatient Reimbursement Overview

DRG 019 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes